rAAVen and Myrtelle Expand Partnership for Capsid Validation

rAAVen Therapeutics has gone into an agreement, for a continuous partnership with Myrtelle, Inc. In the new collaboration rAAVen will validate a defined number of capsids from the previously performed oligodendrocyte screening assay.